Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT07026370

Chinese Population Health and Multimorbidity Study

The Chinese Population Health and Multimorbidity Study (CPHMS; initially named China Pulmonary Health Study, CPHS) was a large-scale epidemiological survey designed to investigate the pulmonary health of Chinese adults aged 20 years or older leveraging a multistage stratified sampling scheme between 2011 and 2014 in mainland China. Briefly, a total number of 57,779 local residents were recruited from 10 representative provinces and municipalities and were invited to participate in the study. A final number of 50,991 adults who met the major inclusion criteria could be considered in further analyses.

In order to investigate the changes of pulmonary health and disease status (e.g. occurrence and development of chronic respiratory diseases and other important relevant multimorbidities, lung function indices, etc.) and corresponding impact factors in the CPHMS study population, we plan to initiate the first round of follow-up investigation between 2025 and 2027 (planned) , i.e. more than 10 years after the baseline survey.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • (1) the individuals who participated in the CPHMS baseline survey;
  • (2) their ID number and phone number are available;
  • (3) sign the informed consent.

Exclusion criteria

  • (1) incapable of taking pre- and post-bronchodilator spirometry tests;
  • (2) request to withdraw the informed consent;
  • (3) terminate due to medical or ethical considerations judged by the investigators and/or ethics committee.

Treatment and study plan

Primary outcomes

  1. Occurrence of multimorbidities

    Time frame: Since the year of baseline survey till the year of 2025 and 2027 (the first round of follow-up investigation of CPHMS)

    Occurrence of chronic respiratory diseases, cardiovascular and cerebrovascular diseases, malignant tumors, and/or metabolic diseases, etc.

Secondary outcomes

  1. Changes of lung function, forced expiratory volume in one second (FEV1)

    Time frame: Since the year of baseline survey till the year of 2025 and 2027 (the first round of follow-up investigation of CPHMS)

    Changes of pre- and post-bronchodilator spirometry test indices, FEV1

  2. Changes of lung function, forced vital capacity (FVC)

    Time frame: Since the year of baseline survey till the year of 2025 and 2027 (the first round of follow-up investigation of CPHMS)

    Changes of pre- and post-bronchodilator spirometry test indices, FVC

  3. Changes of lung function, FEV1/FVC

    Time frame: Since the year of baseline survey till the year of 2025 and 2027 (the first round of follow-up investigation of CPHMS)

    Changes of pre- and post-bronchodilator spirometry test indices, FEV1/FVC

  4. Changes of lung function, the percentage of measured FEV1 value to the predicted value (FEV1%pred)

    Time frame: Since the year of baseline survey till the year of 2025 and 2027 (the first round of follow-up investigation of CPHMS)

    Changes of pre- and post-bronchodilator spirometry test indices, FEV1%pred

Sponsors and collaborators

Lead sponsor

China-Japan Friendship Hospital

Other

Registry information

Official study title

The Chinese Population Health and Multimorbidity Study: Baseline Survey, and Follow-up Investigation

Acronym: CPHMS

Important dates

Study start
2011
Primary completion
2027
Study completion
2027
First posted
Jun 18, 2025
Registry last updated
Mar 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.